AUC

Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219

Retrieved on: 
Monday, April 1, 2024
Diagnosis, Health, Regeneration, Learning, Glycated hemoglobin, Menin, C-peptide, Insulin, Diabetes, AUC, Patient, Fasting, MD, Metformin, Person, Cancer, Safety, A1C, DSM-IV codes, Pharmaceutical industry

REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced initial response data from the first two type 1 diabetes patients treated with BMF-219 in the ongoing Phase II study (COVALENT-112).

Key Points: 
  • “We are very excited to announce the initial response data from the first two type 1 diabetes patients enrolled in the COVALENT-112 study.
  • Both patients showed improvement in measures of beta-cell function after only 4 weeks of dosing with BMF-219.
  • The trial includes an open label portion for adults with type 1 diabetes up to 15 years since diagnosis.
  • It has been exciting to participate in this study and explore this new pathway for the benefit of our patients.

Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans

Retrieved on: 
Monday, April 1, 2024
CSF, Tmax, AUC, Patient, Cerebrospinal fluid, Cmax, Kinetics, APP, SILK

MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced the publication of new data from an earlier study supporting buntanetap as a translational inhibitor of amyloid precursor protein (APP) in patients with early Alzheimer’s Disease (AD).

Key Points: 
  • Buntanetap is an oral molecule that selectively binds to an iron-responsive element in the mRNA of APP and other neurotoxic proteins and inhibits their translation.
  • Through this mechanism, buntanetap was shown to decrease the production of amyloid beta (Aβ), a key hallmark in AD.
  • Here, SILK was used to measure the kinetics of APP in early AD patients and to quantify Aβ40 in CSF.
  • Notably, the analysis of adverse events demonstrated no dose-dependent effect of buntanetap compared to placebo, affirming the drug’s safety and tolerability.

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

Retrieved on: 
Thursday, March 28, 2024
AUC, Patient, Sepsis, Blood, Hospital, FDA, Vaccine

LEXINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the United States, has been extended through March 31, 2025.

Key Points: 
  • LEXINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the United States, has been extended through March 31, 2025.
  • The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bacteria® Panel and the T2Candida® Panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood.
  • “We are pleased to extend our multi-year agreement with Vizient, the nation’s largest group purchasing organization.
  • This reiterates the continued value that our products offer to patients suspected of sepsis,” stated John Sperzel, Chairman and CEO of T2 Biosystems.

Media Advisory: DoseMe Bioinformatician and Chief Science and Strategy Officer Co-Author Abstract Big Data Bayesian Truths to Be Covered in Oral Presentation at the 24th ECCMID Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Health, Infectious Diseases, Hospitals, Health Technology, Genetics, Clinical Trials, Congress, Midwestern University, BCPS, Doctor of Pharmacy, Professor, AUC, Patient, Big data, Vancomycin, Safety, ESCMID, ECCMID, European, Infection, Pharmaceutical industry

ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.

Key Points: 
  • ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.
  • Abstract co-authored Dr. Sharmeen Roy, PharmD, BCPS , Chief Strategy and Science Officer and Paul Sabourenkov , Lead Bioinformatician at DoseMe.
  • What: Abstract 05305, Big Data Bayesian Truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.
  • Details: Title: Big data Bayesian truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

Retrieved on: 
Monday, April 8, 2024
Research, Surgery, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, General Health, Science, Biopsy, Reward, Plasma, International Society, Cohort (statistics), Physician, Risk, AUC, Nucleic acid thermodynamics, Patient, Journal, DNA, Lung transplantation, Heart transplantation, MD, NIH, NTRA, Hospital, Molecule, Bangladesh Technical Education Board, Medicare, Oportunidades, Annual general meeting, NPV

“We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.

Key Points: 
  • “We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.
  • That study showed the Prospera Heart test had an overall area under the curve (AUC) of 0.86 for identifying acute rejection in over 800 samples from 200 adults with heart transplants.
  • The DTRT-2 (DNA-Based Transplant Rejection Test) study, published recently in Pediatric Transplantation , was sponsored by the National Institutes of Health (NIH).
  • A total of 487 samples from 160 heart transplant recipients were evaluated, of which 78 were pediatric and 82 were adult patients.

AvaSure Analytics™ Portal Launches with National Database of Comparative Provider Data

Retrieved on: 
Monday, April 8, 2024
RN, Microsoft, Health, ROI, Organization, Benchmarking, Pressure, Risk, Patient, Hospital, AUC, MSN, Love, Patient safety, Intelligence, Workplace violence, Nursing

BELMONT, Mich., April 8, 2024 /PRNewswire/ -- On the heels of its breakthrough innovation with the AvaSure Episodic solution that allows hospitals to transform their virtual care model, AvaSure has announced significant enhancements to its industry-leading analytics portal that further advances its AI-powered Intelligent Virtual Care platform. The AvaSure Analytics™ portal has been revamped with Microsoft PowerBI tools that enable healthcare providers to conduct deep analysis of critical metrics. As the only comparative database of its kind, AvaSure enables benchmarking an organization's virtual care program performance against more than 800 hospitals nationwide, including a wide range of sizes and types, to drive care quality improvements and return on investment.

Key Points: 
  • The AvaSure Analytics™ portal has been revamped with Microsoft PowerBI tools that enable healthcare providers to conduct deep analysis of critical metrics.
  • "The AvaSure platform has logged over 145 million hours monitoring nearly 2 million patients across the country, consistently delivering program results that improve patient safety while reducing costs," said Adam McMullin, CEO of AvaSure.
  • Amid persistent staffing shortages and rising pressure to control costs, virtual care has become essential for hospitals looking to adapt.
  • To learn more about AvaSure analytics, click here or stop by AvaSure's AONL booth #1112 in New Orleans, April 8-11.

NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digital Health

Retrieved on: 
Monday, March 18, 2024
Nexus, Cloud, Hewlett Packard Enterprise, Azure, GTC, Google Cloud, Health, Metropolis, Patient, History, Orion, LLM, Therapy, San Jose Convention Center, Microsoft, Synthetic media, Vanilla, SAN, Oracle Cloud, 3D, AUC, Protein folding, AWS, Chemistry, Hippocrates, Flywheel, Amgen, Data management, Drug discovery, Acceleration, Hospital, Cadence, AI, Medtech, Dell Technologies, Amazon Web Services, API, CPU, VISTA, Supermicro, Biology, NIM, Universal, Collection, NVIDIA, Generative, Medical device

The microservices, 25 of which launched today, can accelerate transformation for healthcare companies as generative AI introduces numerous opportunities for pharmaceutical companies, doctors and hospitals.

Key Points: 
  • The microservices, 25 of which launched today, can accelerate transformation for healthcare companies as generative AI introduces numerous opportunities for pharmaceutical companies, doctors and hospitals.
  • These include screening for trillions of drug compounds to advance medicine, gathering better patient data to aid early disease detection and implementing smarter digital assistants.
  • “By helping healthcare companies easily build and manage AI solutions, we’re enabling them to harness the full power and potential of generative AI.”
    The new suite of healthcare microservices includes NVIDIA NIM , which provides optimized inference for a growing collection of models across imaging, medtech, drug discovery and digital health.
  • Hippocratic AI is developing task-specific Generative AI Healthcare Agents, powered by the company’s safety-focused LLM for healthcare, connected to NVIDIA Avatar Cloud Engine microservices and will utilize NVIDIA NIM for low-latency inferencing and speech recognition.

Robinhood Markets, Inc. Reports February 2024 Operating Data

Retrieved on: 
Wednesday, March 13, 2024
Crypto, AUC, Robinhood Markets, Net, Cryptocurrency

MENLO PARK, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today reported selected monthly operating data for February 2024:

Key Points: 
  • MENLO PARK, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today reported selected monthly operating data for February 2024:
    Funded Customers at the end of February were 23.6 million, up approximately 130 thousand from January 2024.
  • Assets Under Custody (AUC) at the end of February were $118.7 billion, up 16% from January 2024.
  • Net Deposits were $3.6 billion in February, translating to a 42% annualized growth rate relative to January 2024 AUC.
  • Total Cash Sweep Balances at the end of February were $18.1 billion, up $1.3 billion or 8% from the end of January 2024.

ZOLL Receives Innovative Technology Contract from Vizient for TherOx SuperSaturated Oxygen (SSO2) Therapy

Retrieved on: 
Tuesday, April 2, 2024
Surgery, Medical Devices, Hospitals, Health, Cardiology, Angioplasty, Asahi Kasei, Patient, Cardiac muscle, Facial muscles, Mortality, Splenic infarction, AUC, STEMI, LAD, Heart, Safety, Patient safety, FDA, Nursing

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has received an Innovative Technology contract from Vizient, Inc. , the nation’s largest provider-driven healthcare performance improvement company.

Key Points: 
  • ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has received an Innovative Technology contract from Vizient, Inc. , the nation’s largest provider-driven healthcare performance improvement company.
  • Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient’s Innovative Technology Program.
  • Through its Innovative Technology Program , Vizient works with customer-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare.
  • Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle.

Adtalem Achieves 97% First-Time Residency Attainment Rate and Growing1

Retrieved on: 
Monday, March 25, 2024
General Health, Health, Continuing, University, Education, Obstetrics, Adtalem Global Education, Gynaecology, American University, Med-Peds, ATGE, Physician, RUSM, AUC, Internal, Black, Student, Orthopedic surgery, Health equity, Nursing

These students and graduates will aid in combating the physician shortage that could exceed 120,000 by 2034.

Key Points: 
  • These students and graduates will aid in combating the physician shortage that could exceed 120,000 by 2034.
  • The success of this year's match reflects the quality of Adtalem's programs and the strong demand for its medical school graduates.
  • For comprehensive lists of residency placements, please visit the AUC and RUSM websites.
  • To learn more about Adtalem’s Match Day 2024, visit the Adtalem Newsroom .